Antibodies against a protein entitled 161p2f10b

Abstract

Antibodies and methods of using same against products of the gene designated 161P2F10B and its encoded protein are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein or a fragment thereof, can be used to elicit a humoral or cellular immune response.

1 . An antibody or fragment thereof that specifically binds to a protein comprising the amino acid sequence of SEQ ID NO: 745. 
     
     
         2 . The antibody or fragment thereof of  claim 1 , which is a monoclonal antibody. 
     
     
         3 . The antibody or fragment thereof of  claim 1 , wherein the monoclonal antibody is a single chain monoclonal antibody. 
     
     
         4 . The antibody or fragment thereof of  claim 1 , wherein the fragment thereof is selected from the group consisting of Fab, F(ab′)2, Fv and sFv fragment. 
     
     
         5 . The antibody or fragment thereof of  claim 1 , wherein the antibody is a human antibody, a humanized antibody, or a chimeric antibody. 
     
     
         6 . The antibody or fragment thereof of  claim 1  which is labeled with an agent. 
     
     
         7 . The antibody or fragment thereof of  claim 6 , wherein the agent is a diagnostic agent or a cytotoxic agent. 
     
     
         8 . The antibody or fragment thereof of  claim 7 , wherein the cytotoxic agent is selected from the group consisting of radioactive isotopes, chemotherapeutic agents and toxins. 
     
     
         9 . The antibody or fragment thereof of  claim 8 , wherein the radioactive isotope is selected from the group consisting of At 211 , I 131 , I 125 , Y 90 , Re 186 , Re 188 , Sm 153 , Bi 212 , P 32  and radioactive isotopes of Lu. 
     
     
         10 . The antibody or fragment thereof of  claim 8 , wherein the chemotherapeutic agent is selected from the group consisting of taxol, actinomycin, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, gelonin, and calicheamicin. 
     
     
         11 . The antibody or fragment thereof of  claim 8 , wherein the toxin is selected from the group consisting of diphtheria toxin, enomycin, phenomycin, Pseudomonas exotoxin (PE) A, PE40, abrin, abrin A chain, mitogellin, modeccin A chain, and alpha-sarcin. 
     
     
         12 . A non-human transgenic animal that produces an antibody that specifically binds to a protein comprising the amino acid sequence of SEQ ID NO: 745. 
     
     
         13 . A hybridoma that produces the monoclonal antibody of  claim 2 . 
     
     
         14 . A vector comprising a polynucleotide that encodes a single chain monoclonal antibody that specifically binds to a protein comprising the amino acid sequence of SEQ ID NO: 745. 
     
     
         15 . A method of delivering an agent to a cell that expresses 161P2F10B, comprising:
 providing the agent conjugated to an antibody or fragment thereof that specifically binds to a protein comprising the amino acid sequence of SEQ ID NO: 745; and,   exposing the cell to the antibody-agent or fragment-agent conjugate.   
     
     
         16 . The method of  claim 15 , which is labeled with an agent. 
     
     
         17 . The method of  claim 15 , wherein the agent is a diagnostic agent or a cytotoxic agent. 
     
     
         18 . The method of  claim 17 , wherein the cytotoxic agent is selected from the group consisting of radioactive isotopes, chemotherapeutic agents and toxins. 
     
     
         19 . The method of  claim 18 , wherein the radioactive isotope is selected from the group consisting of At 211 , I 131 , I 125 , Y 90 , Re 186 , Re 188 , Sm 153 , Bi 212 , P 32  and radioactive isotopes of Lu. 
     
     
         20 . The method of  claim 18 , wherein the chemotherapeutic agent is selected from the group consisting of taxol, actinomycin, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, gelonin, and calicheamicin. 
     
     
         21 . The method of  claim 18 , wherein the toxin is selected from the group consisting of diphtheria toxin, enomycin, phenomycin, Pseudomonas exotoxin (PE) A, PE40, abrin, abrin A chain, mitogellin, modeccin A chain, and alpha-sarcin. 
     
     
         22 . A method of generating a mammalian immune response, comprising:
 exposing cells of the mammal's immune system to an immunogenic portion of   a) a protein comprising the amino acid sequence of SEQ ID NO: 745 or   b) a nucleotide sequence that encodes said protein;   whereby an immune response is generated to the protein.   
     
     
         23 . The method of  claim 22 , wherein the protein comprising the amino acid sequence of SEQ ID NO: 745, wherein the protein comprises at least one T cell or at least one B cell epitope. 
     
     
         24 . The method of  claim 23  wherein the immune response comprises an induced B cell that generates antibodies that specifically bind the protein comprising the amino acid sequence of SEQ ID NO: 745. 
     
     
         25 . The method of  claim 23  wherein the immune response comprises activation of a cytotoxic T cell (CTL), whereby the activated CTL kills an autologous cell that expresses the protein comprising the amino acid sequence of SEQ ID NO: 745. 
     
     
         26 . The method of  claim 25  wherein the immune response comprises a helper T cell (HTL), whereby the activated HTL secretes cytokines that facilitate the cytotoxic activity of a cytotoxic T cell (CTL) or the antibody producing activity of a B cell. 
     
     
         27 . An assay for detecting the presence of a protein comprising the amino acid sequence of SEQ ID NO: 745 in a biological sample and a normal sample obtained from a patient who has or who is suspected of having cancer, comprising:
 contacting the biological sample and the normal sample with an antibody or fragment thereof that specifically binds to the protein comprising the amino acid sequence of SEQ ID NO: 745; and,   determining if the antibody binds to the biological sample or the normal sample, whereby binding indicates the presence of the protein.   
     
     
         28 . A method for detecting expression levels of a 161P2F10B gene product in a biological sample and a normal sample obtained from a patient who has or who is suspected of having cancer, comprising:
 determining expression levels of the 161P2F10B gene product in the biological sample and the normal sample obtained from the patient; and   comparing the expression levels of the 161P2F10B gene product detected in the biological sample and the normal sample obtained from the patient, wherein the 161P2F10B gene product is selected from the group consisting of 161P2F10B mRNA or a protein comprising the amino acid sequence of SEQ ID NO: 745.   
     
     
         29 . The method of  claim 28 , whereby the presence of elevated gene products 161P2F10B mRNA or 161P2F10B protein in the biological sample relative to the normal sample indicates the presence of a cancer in the biological sample. 
     
     
         30 . The method of  claim 28  wherein the cancer occurs in a tissue selected from the group consisting of breast, colon, kidney, lung, ovary, pancreas, and prostate.